All In Biotech

Drug Trial Radar · NCT05583227

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 368 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

368

Actual

Start

Nov 10, 2022

Primary completion

Jul 14, 2026

Study completion Mar 23, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Amgen
First posted
Oct 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).

Conditions

  • Eosinophilic Esophagitis

Interventions

  • TezepelumabBiological

    Tezepelumab subcutaneous injection

  • TezepelumabBiological

    Tezepelumab subcutaneous injection

  • PlaceboOther

    Placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levelsTime frame: Week 24
  2. Change from baseline in DSQ (Dysphagia Symptom Questionnaire) scoreTime frame: Week 24

Locations

124 sites in 22 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Los Angeles, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Inverness, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Saint Augustine, Florida

  • Research Site

    Normal, Illinois

  • Research Site

    Iowa City, Iowa

  • Research Site

    Topeka, Kansas

  • Research Site

    White Marsh, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Chesterfield, Michigan

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Ocean City, New Jersey

  • Research Site

    Brooklyn, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Uniontown, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Elizabeth Vale, Australia

  • Research Site

    Kogarah, Australia

  • Research Site

    South Brisbane, Australia

  • Research Site

    Woolloongabba, Australia

  • Research Site

    Vienna, Austria

  • Research Site

    Wels, Austria

  • Research Site

    Bruges, Belgium

  • Research Site

    Edegem, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Botucatu, Brazil

  • Research Site

    Brasília, Brazil

  • Research Site

    Caxias do Sul, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Porto Alegre, Brazil

Showing 40 of 124 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.